Atlas Spine, Inc.
$31.3K 17 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Vitrolife Inc.
Vitrolife Inc. reported $31,260.26 across General Payments, Research, and Ownership to 38 physicians and teaching hospitals across 38 transactions.
- $31.3K Below-median payer
- All-tracks total
- 38 Below-median volume
- Transactions
- 38 Below-median reach
- Recipients
- +$24.5K
- General Payments vs PY2023
Vitrolife Inc. reported $31,260.26 across all CMS Open Payments tracks (General + Research + Ownership) to 38 physicians and teaching hospitals in Program Year 2024 - ranking #1462 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $31,260.26, averaging $822.64 per recipient.
Vitrolife Inc.'s payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
20/100
Total payments
F
10/100
Transaction volume
F
10/100
Physician reach
F
10/100
Payment type diversity
D
50/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer vitrolife-inc Vitrolife Inc.
$31.3K · #1462/1,925 · 0.0% industry · PY2024
- TOT $31.3K
- RANK #1462
- SHARE 0.0%
- TXN 38
- RCP 38
- CAT 4
- GEN $31.3K
- ΔGEN +$24.5K
- TOP1 48.0%
- PY 2024
Volume peers
Nearest volume peer: Atlas Spine, Inc. ($31.3K)
Vitrolife Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Vitrolife Inc.'s CMS-reported General Payments increased by $24.5K (+359.4%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: VITROLIFE INC.PY2023: VITROLIFE INC.PY2024: Vitrolife Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $6,805.16
- PY2024
- $31,260.26
What the Data Shows for Vitrolife Inc.
CMS Open Payments is not a single ledger: the all-tracks total shown above is General Payments plus Research Payments plus Ownership/Investment interests, each with its own disclosure rules. For Vitrolife Inc. that figure is drawn almost entirely from the General Payments track (day-to-day consulting, meals, travel and speaking fees). Data for a given Program Year arrives roughly a year after the period it covers; our methodology page documents the release cadence and how we standardize the tracks for cross-company comparison.
Of the 4 general-payment categories charted below, "Debt Forgiveness" is the largest at $15.1K across 29 transactions, 48.4% of this company's General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
Vitrolife Inc. made 4 types of general payments. "Debt Forgiveness" is the largest category at $15.1K, 48.4% of General Payments.
Vitrolife Inc. reports 4 general-payment categories - the top three are Debt Forgiveness (48.4%), Consulting Fee (48.0%), and Honoraria (3.2%). The remaining 1 category make up 0.4% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How Vitrolife Inc. divides its payments
Ranked by total dollars reported per category
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Debt Forgiveness | $15.1K | 29 | 48.4% |
| Consulting Fee | $15.0K | 5 | 48.0% |
| Honoraria | $1.0K | 1 | 3.2% |
| Food and Beverage | $118.98 | 3 | 0.4% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $25,438.09 (81.4%) of $31,260.26 in this company's General Payments records across 33 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Vitrolife Inc.
The five named recipients with the highest reported General Payments from this company
- 1
Mitchell Rosen
$15,000.00 across 5 reported transactions
- 2
Jaime Vasquez
$5,036.69 across 1 reported transactions
- 3
Ucsf Medical Center
$2,231.38 across 2 reported transactions
- 4
Barnes-Jewish Hospital
$1,945.02 across 1 reported transactions
- 5
Northwestern Memorial Hospital
$1,225.00 across 1 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Vitrolife Inc. ranks #1462 of 1,925 by total payments (bottom 24% by spend) but is notably more concentrated than that alone would suggest -- #615 of 1,838 by HHI (top 33% most concentrated). Its payments land on an unusually narrow set of recipients for its spend size.
View all 12 companies in this HHI neighborhood as a list
- Hyperfine Operations, Inc. : $52.4K total payments, HHI 2743
- 3NT Medical : $11.0K total payments, HHI 2735
- Boehringer Ingelheim Pharma GmbH & Co.KG : $27.7K total payments, HHI 2733
- Carter Bloodcare : $22.6K total payments, HHI 2730
- Kyowa Kirin Services Ltd : $24.7K total payments, HHI 2718
- Dentsply Sirona Orthodontics Inc : $133.4K total payments, HHI 2714
- Vitrolife Inc. (this company) : $31.3K total payments, HHI 2698
- Bard Peripheral Vascular, Inc. : $4.6M total payments, HHI 2695
- Eisai Co., Ltd. : $54.3K total payments, HHI 2691
- Bonebridge Inc. : $41.9K total payments, HHI 2676
- Spinecraft, LLC : $201.8K total payments, HHI 2668
- Longeviti Neuro Solutions LLC : $59.9K total payments, HHI 2668
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Vitrolife Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Vitrolife Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Vitrolife Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
Catheter Precision Inc.
$31.3K 40 recipients
Compare payment profiles
ProgenaCare Global, LLC
$31.3K 385 recipients
Compare payment profiles
Prexion, Inc.
$31.5K 23 recipients
Compare payment profiles
Lupin Inc.
$31.5K 12 recipients
Compare payment profiles
Optos plc
$31.7K 31 recipients
Compare payment profiles
Put this to use
Vitrolife Inc. ranks #1462 of 1,925 by all-tracks total payments, led by "Debt Forgiveness".
- See how manufacturer spending compares across the full leaderboard. Top 100 by total payments
- Compare "Debt Forgiveness" spend across every manufacturer, not just Vitrolife Inc.. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.